Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.56 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 11/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20040969 | 0.88 | SLC22A12 (0.55) | SLC22A12TAS2R14ARCNR2 | |
| SCHEMBL546976 | 0.81 | SLC22A12 (0.55) | SLC22A12TAS2R14AR | |
| SCHEMBL8410428 | 0.80 | ALDH1A1 (0.44) | SLC22A12 | |
| SCHEMBL14730465 | 0.79 | GRM4 (0.48) | SLC22A12ARCNR2 | |
| SCHEMBL31173121 | 0.77 | KIF11 (0.47) | SLC22A12AR | |
| SCHEMBL16682648 | 0.77 | KIF11 (0.47) | SLC22A12AR | |
| SCHEMBL19287089 | 0.77 | KIF11 (0.50) | SLC22A12CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL8410032 | 0.75 | SLC22A12 (0.51) | SLC22A12 | |
| SCHEMBL19144095 | 0.75 | EGLN2 (0.50) | — | |
| SCHEMBL23974261 | 0.75 | NOTUM (0.46) | TAS2R14CCNE2CDK4CCND1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003328-A | Diaryl hydantoin compounds | 加利福尼亚大学董事会 | 2023-04-25 | — | — | CN | claimed |
| EP-3020706-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2015042170-A1 | COMPOSITIONS AND USES OF COMBINATIONS OF DIM-RELATED INDOLES AND SELECTED ANTI-ANDROGEN COMPOUNDS | WAYNE STATE UNIVERSITY (US) | 2015-03-26 | — | — | WO | claimed |
| WO-2013067142-A1 | COMPOUNDS AND TREATMENT METHODS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-10 | — | — | WO | claimed |
| EP-2561871-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2013-02-27 | — | — | EP | claimed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | claimed |
| EP-1893196-A4 | DIARYLHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | claimed |
| JP-2008540523-A | — | — | 2008-11-20 | — | — | JP | claimed |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-12 | — | — | US | claimed |
| EP-1893196-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-05 | — | — | EP | claimed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | claimed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | claimed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | claimed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| CN-116003328-A | Diaryl hydantoin compounds | 加利福尼亚大学董事会 | 2023-04-25 | — | — | CN | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2007127010-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | SLC22A12 1831/4885TAS2R14 4346/4885AR 2/4885 |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | AR, LHCGR, KLK3 | SLC22A12 3499/4885TAS2R14 2294/4885AR 1/4885 |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | AR, NR5A1, SHBG | SLC22A12 2383/4885TAS2R14 2056/4885AR 1/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | SLC22A12 3165/4885TAS2R14 2461/4885AR 1/4885 |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | FAP, LEF1, LPXN | SLC22A12 958/4885TAS2R14 4156/4885AR 11/4885 |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | SLC22A12 1831/4885TAS2R14 4346/4885AR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.